- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00662129
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Phase II Trial of Albumin-Bound Paclitaxel in Combination With Gemcitabine and Bevacizumab in Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving combination chemotherapy together with bevacizumab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving paclitaxel albumin-stabilized nanoparticle formulation and gemcitabine together with bevacizumab works in treating patients with metastatic breast cancer.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
OBJECTIVES:
Primary
- To determine the 6-month progression-free survival rate of patients with metastatic breast cancer treated with paclitaxel albumin-stabilized nanoparticle formulation, gemcitabine hydrochloride, and bevacizumab.
Secondary
- To determine the overall survival of patients treated with this regimen.
- To determine the progression-free survival of patients treated with this regimen.
- To determine the confirmed response rate in patients treated with this regimen.
- To determine the duration of response in patients treated with this regimen.
- To determine the time to treatment failure in patients treated with this regimen.
- To determine the quality of life of patients treated with this regimen.
OUTLINE: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and after every other course, and then after completion of treatment.
After completion of study treatment, patients are followed periodically for 5 years.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Scottsdale, Arizona, Verenigde Staten, 85259-5499
- Mayo Clinic Scottsdale
-
-
Connecticut
-
Hartford, Connecticut, Verenigde Staten, 06105
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32224
- Mayo Clinic - Jacksonville
-
-
Indiana
-
Beech Grove, Indiana, Verenigde Staten, 46107
- St. Francis Hospital and Health Centers - Beech Grove Campus
-
Richmond, Indiana, Verenigde Staten, 47374
- Reid Hospital & Health Care Services
-
-
Iowa
-
Cedar Rapids, Iowa, Verenigde Staten, 52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids, Iowa, Verenigde Staten, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Clive, Iowa, Verenigde Staten, 50325
- Medical Oncology and Hematology Associates - West Des Moines
-
Des Moines, Iowa, Verenigde Staten, 50309
- CCOP - Iowa Oncology Research Association
-
Des Moines, Iowa, Verenigde Staten, 50309
- John Stoddard Cancer Center at Iowa Methodist Medical Center
-
Des Moines, Iowa, Verenigde Staten, 50309
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center
-
Des Moines, Iowa, Verenigde Staten, 50314
- Medical Oncology and Hematology Associates at Mercy Cancer Center
-
Des Moines, Iowa, Verenigde Staten, 50314
- Mercy Cancer Center at Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Verenigde Staten, 50316
- John Stoddard Cancer Center at Iowa Lutheran Hospital
-
Mason City, Iowa, Verenigde Staten, 50401
- Mercy Cancer Center at Mercy Medical Center - North Iowa
-
Ottumwa, Iowa, Verenigde Staten, 52501
- McCreery Cancer Center at Ottumwa Regional
-
Sioux City, Iowa, Verenigde Staten, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, Verenigde Staten, 51104
- St. Luke's Regional Medical Center
-
Sioux City, Iowa, Verenigde Staten, 51104
- Mercy Medical Center - Sioux City
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, Verenigde Staten, 48106
- CCOP - Michigan Cancer Research Consortium
-
Battle Creek, Michigan, Verenigde Staten, 49017
- Battle Creek Health System Cancer Care Center
-
Big Rapids, Michigan, Verenigde Staten, 49307
- Mecosta County Medical Center
-
Dearborn, Michigan, Verenigde Staten, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Flint, Michigan, Verenigde Staten, 48503
- Hurley Medical Center
-
Flint, Michigan, Verenigde Staten, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Grosse Pointe Woods, Michigan, Verenigde Staten, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Jackson, Michigan, Verenigde Staten, 49201
- Foote Memorial Hospital
-
Lansing, Michigan, Verenigde Staten, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, Verenigde Staten, 48154
- St. Mary Mercy Hospital
-
Muskegon, Michigan, Verenigde Staten, 49443
- Mercy General Health Partners
-
Pontiac, Michigan, Verenigde Staten, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, Verenigde Staten, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, Verenigde Staten, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Traverse City, Michigan, Verenigde Staten, 49684
- Munson Medical Center
-
Warren, Michigan, Verenigde Staten, 48093
- St. John Macomb Hospital
-
Wyoming, Michigan, Verenigde Staten, 49519
- Metro Health Hospital
-
-
Minnesota
-
Alexandria, Minnesota, Verenigde Staten, 56308
-
Burnsville, Minnesota, Verenigde Staten, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Verenigde Staten, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth, Minnesota, Verenigde Staten, 55805
- CCOP - Duluth
-
Duluth, Minnesota, Verenigde Staten, 55805-1983
- Duluth Clinic Cancer Center - Duluth
-
Duluth, Minnesota, Verenigde Staten, 55805
- Miller - Dwan Medical Center
-
Edina, Minnesota, Verenigde Staten, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Verenigde Staten, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, Verenigde Staten, 55350
- Hutchinson Area Health Care
-
Maplewood, Minnesota, Verenigde Staten, 55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood, Minnesota, Verenigde Staten, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis, Minnesota, Verenigde Staten, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, Verenigde Staten, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, Verenigde Staten, 55422-2900
- Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
-
Rochester, Minnesota, Verenigde Staten, 55905
- Mayo Clinic Cancer Center
-
Saint Cloud, Minnesota, Verenigde Staten, 56303
- CentraCare Clinic - River Campus
-
Saint Cloud, Minnesota, Verenigde Staten, 56303
- Coborn Cancer Center
-
Saint Louis Park, Minnesota, Verenigde Staten, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, Verenigde Staten, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, Verenigde Staten, 55102
- United Hospital
-
Shakopee, Minnesota, Verenigde Staten, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
St. Paul, Minnesota, Verenigde Staten, 55101
- Regions Hospital Cancer Care Center
-
Waconia, Minnesota, Verenigde Staten, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Verenigde Staten, 56201
- Willmar Cancer Center at Rice Memorial Hospital
-
Woodbury, Minnesota, Verenigde Staten, 55125
- Minnesota Oncology Hematology, PA - Woodbury
-
-
Montana
-
Great Falls, Montana, Verenigde Staten, 59405-5309
- Big Sky Oncology
-
Great Falls, Montana, Verenigde Staten, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
-
Nebraska
-
Lincoln, Nebraska, Verenigde Staten, 68510
- Cancer Resource Center - Lincoln
-
Omaha, Nebraska, Verenigde Staten, 68106
- CCOP - Missouri Valley Cancer Consortium
-
Omaha, Nebraska, Verenigde Staten, 68122
- Immanuel Medical Center
-
Omaha, Nebraska, Verenigde Staten, 68124
- Alegant Health Cancer Center at Bergan Mercy Medical Center
-
Omaha, Nebraska, Verenigde Staten, 68131-2197
- Creighton University Medical Center
-
-
North Dakota
-
Bismarck, North Dakota, Verenigde Staten, 58501
- Bismarck Cancer Center
-
Bismarck, North Dakota, Verenigde Staten, 58501
- Medcenter One Hospital Cancer Care Center
-
Bismarck, North Dakota, Verenigde Staten, 58501
- Mid Dakota Clinic, PC
-
Bismarck, North Dakota, Verenigde Staten, 58502
- St. Alexius Medical Center Cancer Center
-
-
Ohio
-
Dayton, Ohio, Verenigde Staten, 45405
- Grandview Hospital
-
Dayton, Ohio, Verenigde Staten, 45406
- Good Samaritan Hospital
-
Dayton, Ohio, Verenigde Staten, 45409
- David L. Rike Cancer Center at Miami Valley Hospital
-
Dayton, Ohio, Verenigde Staten, 45415
- Samaritan North Cancer Care Center
-
Dayton, Ohio, Verenigde Staten, 45420
- CCOP - Dayton
-
Findlay, Ohio, Verenigde Staten, 45840
- Blanchard Valley Medical Associates
-
Franklin, Ohio, Verenigde Staten, 45005-1066
- Middletown Regional Hospital
-
Greenville, Ohio, Verenigde Staten, 45331
- Wayne Hospital
-
Kettering, Ohio, Verenigde Staten, 45429
- Charles F. Kettering Memorial Hospital
-
Troy, Ohio, Verenigde Staten, 45373-1300
- UVMC Cancer Care Center at Upper Valley Medical Center
-
Wilmington, Ohio, Verenigde Staten, 45177
- Clinton Memorial Hospital
-
Xenia, Ohio, Verenigde Staten, 45385
- Ruth G. McMillan Cancer Center at Greene Memorial Hospital
-
-
Oklahoma
-
Tulsa, Oklahoma, Verenigde Staten, 74136
- Natalie Warren Bryant Cancer Center at St. Francis Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Verenigde Staten, 18105
- Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57105
- Medical X-Ray Center, PC
-
Sioux Falls, South Dakota, Verenigde Staten, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed infiltrating breast cancer
- Clinical evidence of metastatic disease
Measurable disease, defined as at least one measurable lesion per RECIST criteria
No non-measurable disease only, defined as all other lesions, including small lesions (longest diameter < 2 cm) and truly non-measurable lesions, including any of the following:
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Inflammatory breast disease
- Lymphangitis cutis/pulmonis
- Abdominal masses that are not confirmed and followed by imaging techniques
- Cystic lesions
- Patients with HER-2/neu positive tumors, must have received prior treatment with trastuzumab (Herceptin®) or have a contraindication for trastuzumab
No evidence of active brain metastasis, including leptomeningeal involvement, on MRI or CT scan
CNS metastasis controlled by prior surgery and/or radiotherapy allowed
- Must be asymptomatic for ≥ 2 months with no evidence of progression prior to study entry
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Life expectancy ≥ 12 weeks
- ECOG performance status 0-1
- ANC ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 9.0 g/dL
- AST and ALT ≤ 2.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 times ULN
- Total bilirubin ≤ 1.5 times ULN
- Creatinine ≤ 1.5 mg/dL
Urine protein:creatinine ratio < 1 or urinalysis < 1+ protein
- Patients discovered to have ≥ 1+ proteinuria at baseline must demonstrate 24-hour urine protein < 1 g
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after completion of study therapy
- Able to complete questionnaires alone or with assistance
- No peripheral neuropathy > grade 1
- No history of allergy or hypersensitivity to albumin-bound paclitaxel, paclitaxel, gemcitabine hydrochloride, bevacizumab, albumin, drug product excipients, or chemically similar agents
- No stage III or IV invasive, non-breast malignancy within the past 5 years
No other active malignancy, except nonmelanoma skin cancer or carcinoma in situ of the cervix
- Patient must not be receiving other specific treatment for a prior malignancy
No uncontrolled hypertension (i.e., blood pressure [BP] > 160/90 mm Hg on ≥ 2 occasions at least 5 minutes apart)
- Patients who have recently started or adjusted antihypertensive medications are eligible providing that BP is < 140/90 mm Hg on any new regimen for ≥ 3 different observations in ≥ 14 days
- No bleeding diathesis or uncontrolled coagulopathy
- No hemoptysis within the past 6 months
- No prior arterial or venous thrombosis within the past 12 months
- No history of cerebrovascular accident
- No history of hypertensive crisis or hypertensive encephalopathy
- No abdominal fistula or gastrointestinal perforation within the past 6 months
- No serious non-healing wound, ulcer, or fracture
No clinically significant cardiac disease, defined as any of the following:
- Congestive heart failure
- Symptomatic coronary artery disease
- Unstable angina
- Cardiac arrhythmias not well controlled with medication
- Myocardial infarction within the past 12 months
- No comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for study entry or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
No prior chemotherapy for metastatic disease
- May have received one prior adjuvant chemotherapy regimen
Prior neoadjuvant chemotherapy allowed
- More than 6 months since prior adjuvant or neoadjuvant taxane (i.e., docetaxel or paclitaxel) therapy
- Prior hormonal therapy in either adjuvant or metastatic setting allowed
More than 4 weeks since prior radiotherapy (except if to a non-target lesion only, or single dose radiation for palliation)
- Prior radiotherapy to a target lesion is allowed provided there has been clear progression of the lesion since radiotherapy was completed
- More than 4 weeks since prior cytotoxic chemotherapeutic agent or investigational drug
- More than 2 weeks since prior and no concurrent acetylsalicylic acid, anticoagulants, or thrombolytic agents (except for once-daily 81 mg acetylsalicylic acid)
- More than 6 weeks since prior major surgery, chemotherapy, or immunologic therapy
More than 1 week since prior minor surgery (e.g., core biopsy)
- Placement of a vascular access device within 7 days is allowed
- More than 3 months since prior neurosurgery
No concurrent treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered
- Trials related to symptom management (Cancer Control) which do not employ hormonal treatments or treatments that may block the path of the targeted agents used in this study may be allowed
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: paclitaxel + gemcitabine + bevacizumab
Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30 minutes and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and after every other course, and then after completion of treatment. After completion of study treatment, patients are followed periodically for 5 years. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
6-month Progression-free Survival (PFS) Rate
Tijdsspanne: at 6 months
|
The primary endpoint of this trial is the 6-month progression-free survival rate.
A patient is considered to be a 6-month progression-free survivor if the patient is 6 months from registration without a documentation of disease progression (note, the patient need not be on study treatment at 6 months to be considered a success).
The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients.
Confidence intervals for the true success proportion will be calculated using the properties of the binomial distribution.
Progression is defined using the RECIST Criteria, as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.
|
at 6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Overall Survival Time
Tijdsspanne: Up to 5 years
|
Overall Survival time is defined as the time from registration to death due to any cause.
The distribution of survival time will be estimated using the method of Kaplan-Meier (1958).
|
Up to 5 years
|
PFS Time
Tijdsspanne: Up to 5 years
|
Progression-free survival time is defined as the time from registration to the earliest date of documentation of disease progression.
If a patient dies without a documentation of disease progression the patient will be considered to have had disease progression at the time of their death.
The distribution of time to progression will be estimated using the method of Kaplan-Meier (1958).
Progression is defined using the RECIST Criteria, as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.
|
Up to 5 years
|
Confirmed Response (Complete or Partial Response) Rate
Tijdsspanne: Up to 5 years
|
A confirmed response is defined to be either a complete response (CR) or partial response (PR) noted as the objective status on 2 consecutive evaluations at least 8 weeks apart.
The confirmed response rate (percentage) will be estimated by the number of confirmed responses in evaluable patients divided by the total number of evaluable patients multiplied by 100.
The appropriate confidence interval will be calculated based on the binomial distribution.
|
Up to 5 years
|
Duration of Response
Tijdsspanne: Up to 5 years
|
Duration of response is defined for all evaluable patients who have achieved a confirmed response as the date at which the patient's earliest best objective status is first noted to be either a CR or PR to the earliest date progression is documented.
If a patient dies subsequent to the confirmed response without a documentation of disease progression, the patient will be considered to have had disease progression at the time of their death.
In the case of a patient failing to return for evaluations before a documentation of disease progression, the patient will be censored for progression on the date of last evaluation.
The distribution of duration of response will be estimated using the method of Kaplan-Meier (1958).
|
Up to 5 years
|
Time to Treatment Failure
Tijdsspanne: Up to 5 years
|
Time to treatment failure is defined to be the time from the date of registration to the date at which the patient is removed from treatment due to progression, adverse events, or refusal.
If the patient is considered to be a major treatment violation or is taken off study as a non-protocol failure, the patient will be censored on the date they were removed from treatment.
The distribution of time to treatment failure will be estimated using the method of Kaplan-Meier (1958).
Progression is defined using the RECIST Criteria, as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one or more new lesions, or unequivocal progression of existing non-target lesions.
|
Up to 5 years
|
Quality of Life, as Measure by the Mean Change in FACT-B TOI Score at Cycle 8
Tijdsspanne: From baseline to end of Cycle 8; Up to 24 weeks
|
Quality of life (QOL) as measured by the mean change (from baseline) in FACT-B (TOI) Trial Outcome Index at Cycle 8 (24 weeks). FACT-B was scored according to the published scoring (*) criteria with higher scores representing better QOL. The FACT-B TOI was the sum of the following FACT-B subscale/scale scores: physical (score range 0-28), functional (score range 0-28), and Breast Cancer Subscale (score range 0-40); range of the FACT-B TOI is 0-96 (the change scores have a possible range of -96 to 96). The mean change and 95% confidence interval are reported below. A one-sample t-test is used to compare the change from baseline to a value of 0. (*)= Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument. J Clin Oncol 1997;15:974-986. |
From baseline to end of Cycle 8; Up to 24 weeks
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie stoel: Donald W. Northfelt, MD, FACP, Mayo Clinic
Publicaties en nuttige links
Algemene publicaties
- Northfelt DW, Dueck AC, Flynn TP, et al.: Phase II trial combining nab-paclitaxel (NP), gemcitabine (G), and bevacizumab (B) in patients (pts) with metastatic breast cancer (MBC): NCCTG N0735. [Abstract] J Clin Oncol 29 (Suppl 15): A-1126, 2011.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Huidziektes
- Neoplasmata
- Neoplasmata per site
- Borst ziekten
- Borstneoplasmata
- Fysiologische effecten van medicijnen
- Moleculaire mechanismen van farmacologische werking
- Anti-infectieuze middelen
- Antivirale middelen
- Enzymremmers
- Antimetabolieten, antineoplastische
- Antimetabolieten
- Antineoplastische middelen
- Immunosuppressieve middelen
- Immunologische factoren
- Tubuline-modulatoren
- Antimitotische middelen
- Mitose modulatoren
- Antineoplastische middelen, fytogeen
- Antineoplastische middelen, immunologisch
- Angiogenese-remmers
- Angiogenese modulerende middelen
- Groei stoffen
- Groeiremmers
- Gemcitabine
- Paclitaxel
- Bevacizumab
- Albumine-gebonden paclitaxel
Andere studie-ID-nummers
- NCCTG-N0735
- NCI-2009-00666 (Register-ID: CTRP (Clinical Trials Reporting System))
- CDR0000593581 (Register-ID: PDQ (Physician Data Query))
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Borstkanker
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University en andere medewerkersVoltooidDe klinische toepassingsgids van Conebeam Breast CTChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
Klinische onderzoeken op gemcitabine hydrochloride
-
Dokuz Eylul UniversityNog niet aan het wervenBlaaskanker | Gemcitabine | BCG | Docetaxel | Intravesicale instillatieKalkoen
-
Insel Gruppe AG, University Hospital BernSwiss Cancer LeagueNog niet aan het werven
-
German Society for Pediatric Oncology and Hematology...Deutsche Krebshilfe e.V., Bonn (Germany)WervingNasofarynxcarcinoom | Nasofaryngeale kanker | Nasofarynxkanker | Nasofaryngeale neoplasmataDuitsland